▶ 調査レポート

痛風治療の世界市場:コルヒチン、抗高尿酸血症薬(尿酸低下薬)、非ステロイド系抗炎症薬(NSAID)、コルチコステロイド、生物学的応答調節剤(バイオロジックス)

• 英文タイトル:Gout Therapeutic Market (Drug Type - Colchicine, Antihyperuricemic Agents (Urate-Lowering Drugs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Biologic Response Modifiers (Biologics); Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。痛風治療の世界市場:コルヒチン、抗高尿酸血症薬(尿酸低下薬)、非ステロイド系抗炎症薬(NSAID)、コルチコステロイド、生物学的応答調節剤(バイオロジックス) / Gout Therapeutic Market (Drug Type - Colchicine, Antihyperuricemic Agents (Urate-Lowering Drugs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Biologic Response Modifiers (Biologics); Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / TPM-JL072資料のイメージです。• レポートコード:TPM-JL072
• 出版社/出版日:Transparency Market Research / 2019年5月21日
• レポート形態:英文、PDF、165ページ
• 納品方法:Eメール
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Global Site License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、痛風治療の世界市場について調べ、痛風治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬種類別(コルヒチン、抗高尿酸血症薬(尿酸低下薬)、非ステロイド系抗炎症薬(NSAID)、コルチコステロイド、生物学的応答調節剤(バイオロジックス))分析、流通チャネル別(病院薬局、小売薬局、オンライン薬局)分析、関連企業情報などをまとめました。
・痛風治療の市場概要
・痛風治療の市場動向
・痛風治療の世界市場規模・予測
・痛風治療市場:薬種類別(コルヒチン、抗高尿酸血症薬(尿酸低下薬)、非ステロイド系抗炎症薬(NSAID)、コルチコステロイド、生物学的応答調節剤(バイオロジックス))
・痛風治療市場:流通チャネル別(病院薬局、小売薬局、オンライン薬局)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

Global Gout Therapeutics Market: Overview

This report studies the current as well as future prospects of the global gout therapeutic market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of gout therapeutic and new players planning to enter the market.

The report comprises an elaborate executive summary, along with a market snapshot, providing overall information on various segments considered in the scope of the study. The section also provides information and data analysis of the global gout therapeutic market in terms of drug type, distribution channel, and region.

Global Gout Therapeutics Market: Key Segments

The global gout therapeutic market has been segmented based on drug type, distribution channel, and region. In terms of drug type, the global market has been classified into colchicine, antihyperuricemic agents (urate-lowering drugs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic response modifiers (Biologics).

Based on distribution channel, the global gout therapeutic market has been divided into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment is expected to dominate the global gout therapeutic market during the forecast period.

Research Approach

The bottom-up approach has been employed to determine the size of the global gout therapeutic market, using various market indicators obtained from secondary sources, which included analysis of launched products and mapping of demand for gout therapeutic of top market players in specific regions.

The top-down approach has been used to derive the market size of different product segments, wherein market size of parent market was obtained through secondary sources and analyzed for sales by narrowing down to revenue percentage for product segment through extensive analysis of investor presentations, press releases, primary interviews, and others.

Data triangulation is based on both secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. Market value and forecast, in terms of US$ Mn, for each segment has been provided for the period from 2017 to 2027.

The report also provides compound annual growth rate (CAGR %) for each segment for the forecast period from 2019 to 2027, considering 2018 as the base year.

The overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have significant impact on the global gout therapeutic market and could influence it in the near future.

Market attractiveness analysis has been provided to explain the intensity of competition in the market across regions. These analyses are likely to help market players take strategic decisions to strengthen their positions and grow their share in the global gout therapeutic market. The report also comprises pipeline analysis and epidemiological overview of gout.

Global Gout Therapeutics Market: Regional Outlook

In terms of region, the global gout therapeutic market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Market size and forecast for each of these regions have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year.

The report also provides market size and forecast for major countries in the above mentioned regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and growth opportunities has been provided in the overview section.

Companies Mentioned in the Report

Some of the major players operating in the global gout therapeutics market are

Takeda Pharmaceutical Company Limited
Teijin Pharma Limited.
Novartis AG, Mylan N.V.
Horizon Pharma plc
Teva Pharmaceutical Industries Ltd.
Hikma Pharmaceuticals PLC
Iroko Pharmaceuticals, LLC
MERCK & CO., Inc.
The global gout therapeutics market has been segmented as follows:

Global Gout Therapeutics Market, by Drug Type

Colchicine
Antihyperuricemic Agents (Urate-Lowering Drugs)
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Biologic Response Modifiers (Biologics)
Global Gout Therapeutics Market, by Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Gout Therapeutics Market, by Region

North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

レポート目次

1.Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Gout Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Component Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gout Therapeutics Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1.Epidemiological Overview of Gout Arthritis
5.2.Pipeline Analysis

6. Global Gout Therapeutics Market Analysis and Forecast, by Component
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
6.3.1. Colchicine
6.3.2. Antihyperuricemic agents (Urate-Lowering Drugs)
6.3.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
6.3.4. Corticosteroids
6.3.5. Biologic Response Modifiers (Biologics)
6.4. Global Gout Therapeutics Market Attractiveness, by Drug Type

7 Global Gout Therapeutics Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Global Gout Therapeutics Market Attractiveness, by Distribution Channel

8. Global Gout Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Gout Therapeutics Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Gout Therapeutics Market Attractiveness, by Country/Region

9. North America Gout Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
9.2.1. Colchicine
9.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
9.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
9.2.4. Corticosteroids
9.2.5. Biologic Response Modifiers (Biologics)
9.3. North America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. North America Gout Therapeutics Market Value Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Gout Therapeutics Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Gout Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
10.2.1. Colchicine
10.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
10.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
10.2.4. Corticosteroids
10.2.5. Biologic Response Modifiers (Biologics)
10.3. Europe Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Europe Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Gout Therapeutics Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific Gout Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Asia Pacific Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
11.2.1. Colchicine
11.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
11.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
11.2.4. Corticosteroids
11.2.5. Biologic Response Modifiers (Biologics)
11.3. Asia Pacific Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Online Pharmacy
11.4. Asia Pacific Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Gout Therapeutics Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America Gout Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Latin America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
12.2.1. Colchicine
12.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
12.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
12.2.4. Corticosteroids
12.2.5. Biologic Response Modifiers (Biologics)
12.3. Latin America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Online Pharmacy
12.4. Latin America Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Gout Therapeutics Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa Gout Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
13.2.1. Colchicine
13.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
13.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
13.2.4. Corticosteroids
13.2.5. Biologic Response Modifiers (Biologics)
13.3. Middle East & Africa Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
13.3.1. Hospital Pharmacy
13.3.2. Retail Pharmacy
13.3.3. Online Pharmacy
13.4. Middle East & Africa Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5.Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Company Profiles
14.1.1. Takeda Pharmaceutical Company Limited
14.1.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.1.2 Product Portfolio
14.1.1.3. SWOT Analysis
14.1.1.4. Strategic Overview
14.1.1.5. Financial Overview
14.1.2. Teijin Pharma Limited
14.1.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.2.2 Product Portfolio
14.1.2.3. SWOT Analysis
14.1.2.4. Strategic Overview
14.1.3. Novartis AG
14.1.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.3.2 Product Portfolio
14.1.3.3. SWOT Analysis
14.1.3.4. Strategic Overview
14.1.3.5. Financial Overview
14.1.4. Mylan N.V.
14.1.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.4.2 Product Portfolio
14.1.4.3. SWOT Analysis
14.1.4.4. Strategic Overview
14.1.4.5. Financial Overview
14.1.5. Horizon Pharma plc.
14.1.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.5.2 Product Portfolio
14.1.5.3. SWOT Analysis
14.1.5.4. Strategic Overview
14.1.5.5. Financial Overview
14.1.6. Teva Pharmaceutical Industries Ltd.
14.1.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.6.2 Product Portfolio
14.1.6.3. SWOT Analysis
14.1.6.4. Strategic Overview
14.1.6.5. Financial Overview
14.1.7 Hikma Pharmaceuticals PLC
14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.7.2 Product Portfolio
14.1.7.3. SWOT Analysis
14.1.7.4. Strategic Overview
14.1.7.5. Financial Overview
14.1.8. Iroko Pharmaceuticals, LLC
14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.7.2 Product Portfolio
14.1.7.3. SWOT Analysis
14.1.7.4. Strategic Overview
14.1.9. MERCK & CO., Inc.
14.1.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.9.2 Product Portfolio
14.1.9.3. SWOT Analysis
14.1.9.4. Strategic Overview
14.1.9.5. Financial Overview

List of Tables

Table 01: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 2: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 3: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 4: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 5: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 6: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel,
2017–2027
Table 7: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 8: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 9: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 10: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 11: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 12: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 13: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 14: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 15: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 16: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 17: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 18: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027